Tyme Technologies Inc.

09/27/2021 | Press release | Distributed by Public on 09/27/2021 04:55

TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment[...]